Physician profile
Naseem Eisa
NPI 1659600112
$3,673.44
in general payments reported to CMS, 2019-2025
29 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $58.56 · 2021: $193 · 2022: $666 · 2023: $450 · 2024: $539 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $564.75 | 2019 | |
| Amgen INC. | $524.35 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $343.52 | 2021-2025 | |
| Novo Nordisk INC | $341.26 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $260.94 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $256.65 | 2020-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $190.74 | 2022-2025 | Mounjaro, Jardiance |
| Antares Pharma, INC. | $145.52 | 2024-2025 | Xyosted |
| Medtronic, INC. | $121.40 | 2022-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.60 | 2022-2025 | Jardiance |
| Insulet Corporation | $99.33 | 2020-2022 | |
| Horizon Therapeutics Plc | $84.58 | 2019-2023 | Tepezza |
| Radius Health, INC. | $77.17 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $74.40 | 2022-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $68.23 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $52.00 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Verity Pharmaceuticals INC. | $50.09 | 2025 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $49.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $46.25 | 2021-2024 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $37.34 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $30.11 | 2025 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $29.37 | 2021-2022 | |
| Tolmar, INC. | $23.90 | 2025 | Jatenzo |
| Mannkind Corporation | $22.96 | 2023 | Afrezza |
| Sequel Med Tech, LLC | $20.16 | 2025 | Twiist |
| Kyowa Kirin, INC. | $16.67 | 2025 | |
| Amarin Pharma, INC. | $13.13 | 2020 | |
| Corcept Therapeutics | $13.09 | 2019 | |
| Merck Sharp & Dohme LLC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naseem Eisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.